Corbus presents Phase 1b CANYON-1 data for CRB-913 at ObesityWeek 2026
Oral CB1 inverse agonist produced 5% placebo-adjusted weight loss at 60 mg over 12 weeks, with discontinuations due to adverse events at 8.3% across cohorts.
SEC filing
2 stories
Oral CB1 inverse agonist produced 5% placebo-adjusted weight loss at 60 mg over 12 weeks, with discontinuations due to adverse events at 8.3% across cohorts.
SEC filing
The company said topline interim results from its pivotal FORTIFI-HN01 study are expected in mid-2027, while cash on hand is projected to fund operations into the first half of 2029.
SEC filing (10)